Dr Beckman reports consulting for JanOne, Medtronic, Merck, Mingsight, Novartis, Regeneron, and Tourmaline. Dr Hussein reports research funding from a Brigham and Women’s Hospital Heart and Vascular Center Faculty Award, a Brigham Department of Surgery Osteen Award, Vascular Therapies, Inc (ACCESS-2 Trial), Humacyte, Inc (V012 Trial), and VenoStent, Inc (SAVE-Fistulas Trial); and consulting for Humacyte, Inc. Dr McGinigle reports research funding from Novo Nordisk Foundation and consulting for Medtronic, Shockwave, and Vascular Technologies. Dr Jaff is a part-time employee of Boston Scientific Corporation. Dr Farber reports receiving grant support from Novo Nordisk Foundation; consulting for Sanifit, LeMaitre, and BioGenCell; and serving on advisory boards for Dialysis-X and iThera Medical. Dr Menard reports support from Janssen. Dr Rosenfield receives income as a consultant or member of a scientific advisory board for Abbott Vascular, Althea Medical, Angiodynamics, Auxetics, Boston Scientific, Contego, InspireMD, Janssen/Johnson & Johnson, Magneto, MedAlliance, Medtronic, Neptune Medical, Philips, Thrombolex, Vantis Vascular, Vasorum, and Vumedi; owns equity or stock options in Access Vascular, Aerami, Althea Medical, Auxetics, Contego, Crossliner, Cruzar Systems, Endospan, Imperative Care/Truvic, Innova Vascular, InspireMD, JanaCare, Magneto, MedAlliance, Neptune Medical, Orchestra, Shockwave, Skydance, Summa Therapeutics, Thrombolex, Vasorum, and Vumedi; serves as a member of the board of directors of the National Pulmonary Embolism Response Team Consortium; and Dr Rosenfield or his institution (on his behalf) receives research grants from National Institutes of Health, Abiomed, Boston Scientific, Novo Nordisk Foundation, Penumbra, and Gettinge-Atrium.